Zonegran(zonisamide)
Zonegran, Zonisade, Zonisamide (zonisamide) is a small molecule pharmaceutical. Zonisamide was first approved as Zonegran on 2000-03-27. It is used to treat epilepsy and partial epilepsies in the USA. It has been approved in Europe to treat epilepsy and partial epilepsies. It is known to target carbonic anhydrase 7, carbonic anhydrase 12, and carbonic anhydrase 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
Trade Name
FDA
EMA
Zonegran, Zonisade, Zonisamide (discontinued: Zonegran, Zonisamide)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Zonisamide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ZONEGRAN | ADVANZ PHARMA | N-020789 RX | 2000-03-27 | 2 products, RLD, RS |
| ZONISADE | Azurity | N-214273 RX | 2022-07-15 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| direct rx | ANDA | 2015-08-12 |
| zonegran | New Drug Application | 2024-12-05 |
| zonisade | New Drug Application | 2023-03-30 |
| zonisamide | ANDA | 2025-07-17 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| epilepsy | EFO_0000474 | D004827 | G40.9 |
| partial epilepsies | EFO_0004263 | D004828 | — |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
87 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Epilepsy | D004827 | EFO_0000474 | G40.9 | 1 | — | 7 | 16 | 8 | 32 |
| Seizures | D012640 | — | G40.4 | — | — | 8 | 7 | 2 | 17 |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | — | 6 | 3 | 1 | 1 | 11 |
| Partial epilepsies | D004828 | EFO_0004263 | — | — | — | 1 | 6 | 2 | 9 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | 3 | 1 | 1 | 1 | 6 |
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | 1 | 2 | 1 | 1 | 5 |
| Weight gain | D015430 | — | — | — | 1 | 2 | 1 | — | 4 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 1 | 1 | 1 | 1 | 3 |
| Drug resistant epilepsy | D000069279 | — | — | — | — | — | 1 | 1 | 2 |
| Intellectual disability | D008607 | EFO_0003847 | F73 | — | — | — | 1 | 1 | 2 |
Show 7 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alcohol drinking | D000428 | EFO_0004329 | — | — | 3 | 2 | — | — | 5 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | 1 | 1 | — | — | 2 |
| Psychotic disorders | D011618 | — | F20.81 | — | 1 | 1 | — | — | 2 |
| Smoking cessation | D016540 | EFO_0004319 | — | — | — | 2 | — | — | 2 |
| Complex partial epilepsy | D017029 | EFO_1000877 | — | — | — | 1 | — | 1 | 2 |
| Tuberous sclerosis | D014402 | — | Q85.1 | — | — | 1 | — | — | 1 |
| Sclerosis | D012598 | — | — | — | — | 1 | — | — | 1 |
| Dystonic disorders | D020821 | — | G24 | — | — | 1 | — | — | 1 |
| Dystonia | D004421 | — | — | — | — | 1 | — | — | 1 |
| Myoclonus | D009207 | — | G25.3 | — | — | 1 | — | — | 1 |
Show 6 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hearing loss | D034381 | EFO_0004238 | H91.9 | 1 | 3 | — | — | — | 3 |
| Noise-induced hearing loss | D006317 | EFO_1001254 | — | 1 | 3 | — | — | — | 3 |
| Deafness | D003638 | EFO_0001063 | H91.9 | 1 | 3 | — | — | — | 3 |
| Central nervous system neoplasms | D016543 | — | — | 1 | 2 | — | — | — | 2 |
| Nervous system neoplasms | D009423 | — | — | 1 | 2 | — | — | — | 2 |
| Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | — | 2 | — | — | — | 2 |
| Sleep apnea syndromes | D012891 | EFO_0003877 | G47.3 | — | 2 | — | — | — | 2 |
| Apnea | D001049 | — | R06.81 | — | 2 | — | — | — | 2 |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | 2 | — | — | — | 2 |
| Traumatic stress disorders | D040921 | — | — | — | 2 | — | — | — | 2 |
Show 9 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 6 | — | — | — | — | 6 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Financial stress | D000086522 | — | — | — | — | — | — | 1 | 1 |
| Developmental disabilities | D002658 | EFO_0003852 | F89 | — | — | — | — | 1 | 1 |
| Weight loss | D015431 | — | — | — | — | — | — | 1 | 1 |
| Acidosis | D000138 | EFO_1000014 | E87.2 | — | — | — | — | 1 | 1 |
| Craniotomy | D003399 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Zonisamide |
| INN | zonisamide |
| Description | Zonisamide is a 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position. It has a role as an anticonvulsant, an antioxidant, a central nervous system drug, a protective agent and a T-type calcium channel blocker. It is a member of 1,2-benzoxazoles and a sulfonamide. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | NS(=O)(=O)Cc1noc2ccccc12 |
Identifiers
| PDB | — |
| CAS-ID | 68291-97-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL750 |
| ChEBI ID | 10127 |
| PubChem CID | 5734 |
| DrugBank | DB00909 |
| UNII ID | 459384H98V (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Zonisamide
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 5,134 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
7,619 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use